利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.014 秒)

    INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO
    2.
    发明申请
    INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO 有权
    感染性体外培养的体外培养物

    公开(公告)号：US20160287688A1

    公开(公告)日：2016-10-06

    申请号：US15095360

    申请日：2016-04-11

    申请人： SANARIA INC.

    发明人： Abraham G. EAPPEN ,  Stephen L. HOFFMAN

    IPC分类号： A61K39/015 ,  C12N1/10

    CPC分类号： A61K39/015 ,  A61K2039/52 ,  A61K2039/522 ,  C12N1/10 ,  Y02A50/412

    摘要： The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

    摘要翻译： 该应用涉及人宿主范围的体外培养的疟原虫子孢子，其中从配子细胞阶段到子孢子期的孢子体在蚊子外部，以及其生产方法。 本文提供的是人宿主范围的体外培养的感染性疟原虫子孢子（SPZ），特别是恶性疟原虫，间日疟原虫，卵白念珠菌，疟原虫和know know属，其中从配子细胞阶段到子孢子期的孢子是外部的 蚊子，以及生产蚊子的方法。

    INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO
    6.
    发明申请
    INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO 有权

    公开(公告)号：US20220257742A1

    公开(公告)日：2022-08-18

    申请号：US17529812

    申请日：2021-11-18

    申请人： Sanaria Inc.

    发明人： Abraham G. EAPPEN ,  Stephen L. HOFFMAN

    IPC分类号： A61K39/015 ,  C12N1/10

    摘要： The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

    SERUM ANTIBODY ASSAY FOR DETERMINING PROTECTION FROM MALARIA, AND PRE-ERYTHROCYTIC SUBUNIT VACCINES
    7.
    发明申请
    SERUM ANTIBODY ASSAY FOR DETERMINING PROTECTION FROM MALARIA, AND PRE-ERYTHROCYTIC SUBUNIT VACCINES 审中-公开
    用于确定疟疾保护的血清抗体测定法和预红细胞亚硝酸盐疫苗

    公开(公告)号：US20160216276A1

    公开(公告)日：2016-07-28

    申请号：US14914869

    申请日：2014-09-02

    申请人： Sanaria Inc. ,  Antigen Discovery, Inc. ,  The United States of America,as represented by the Secretary, Department of Health and Human Service

    发明人： Philip FELGNER ,  Stephen L. HOFFMAN ,  Robert SEDER

    IPC分类号： G01N33/68 ,  A61K39/015

    CPC分类号： G01N33/6854 ,  A61K39/015 ,  G01N2333/445 ,  G01N2469/20 ,  Y02A50/412 ,  Y02A50/58

    摘要： Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.

    摘要翻译： 本文公开了用于鉴定被疟原虫恶性疟原虫保护的个体的诊断测定法。 这种测定法不仅可以用于确定Pf整个寄生虫疫苗对于个体受试者的保护功效，而且还用于接种疫苗接种者的群体。 测定法包括使用表示至少50％Pf的蛋白质组，优选与固相偶联作为固定阵列。 阵列用于探测人类受试者的血清，特别是整个寄生虫疟疾疫苗的人类临床试验的受试者以及公共卫生疫苗接种运动。 具有抗CSP和MSP5多重反应的抗体谱的血清样品的灵敏度为92％至100％，特异性为84％至89％。